Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Vanda (VNDA) today. The company’s shares opened today at $21.40.
Archila noted:
“We believe VNDA’s decision to sue the FDA for what it feels are “unnecessary animal studies” and due to the company’s current refusal to run these studies having resulted in a partial clinical hold on tradipitant, this will certainly raise questions among investors about the clinical timelines for this program and whether or not management is really focused on creating value for its shareholders.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -7.1% and a 36.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Aimmune Therapeutics.
Vanda has an analyst consensus of Moderate Buy, with a price target consensus of $40.33.
See today’s analyst top recommended stocks >>
Based on Vanda’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $7.17 million. In comparison, last year the company had a GAAP net loss of $1.84 million.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
